The cancer genetics testing provider acquired its new business unit from GE Healthcare.
By buying Clarient, NeoGenomics hopes to move closer to its goal of becoming America's top cancer genetic testing lab.
NeoGenomics and GE Healthcare will also collaborate on a bioinformatics initiative for personalized oncology.
The deal gives Axiogenesis access to IP that will allow it to commercialize stem cell-derived assays and disease models for use in drug discovery.
The licenses provide non-exclusive access to the IP for research applications.
General Electric has been awarded
Originally published Oct. 3.
NEW YORK (GenomeWeb) – GE Healthcare today announced a deal between its affiliate Clarient Diagnostic Services and GlaxoSmithKline to create a network of clinical laboratories to identify genetic mutations associated with different tumor types.
Title: Treatment of Cancer by Inhibition of IGFBPs and Clusterin
Patent Number: 8,835,401
Filed: May 29, 2013
GE Healthcare this week launched the illustra Single Cell GenomiPhi DNA amplification kit from.
Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.
The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.
CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.
In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.